OBJECTIVE: Evidence-based techniques were applied to clinical trial data of esomeprazole for maintaining healed erosive esophagitis (EE) to provide a practical, quantitative analysis of its efficacy relative to lansoprazole. METHODS: Patients with a history of heartburn and EE, Los Angeles Grade A-D at baseline, received esomeprazole 40 mg once daily for up to 8 weeks for healing. Those with healed EE were randomized to receive once daily esomeprazole 20 mg (n = 615) or lansoprazole 15 mg (n = 609) for up to 6 months. For this retrospective analysis, the number needed to treat (NNT), the reciprocal of the absolute risk reduction (ARR), was calculated at 6 months for all patients and for subgroups with mild disease (LA Grade A or B) and severe disease (LA Grade C or D). RESULTS: In this evidence-based analysis, it was determined that 11 patients with EE would need to be treated with esomeprazole to prevent one treatment failure that otherwise may occur with lansoprazole regardless of the baseline grade of EE. As the severity of disease increased (LA Grade C or D), the NNT to prevent one relapse that may otherwise have occurred with lansoprazole decreased to 6. CONCLUSIONS: For patients with more severe disease, the NNT was lower, indicating a greater likelihood of therapeutic success with esomeprazole versus lansoprazole. This evidence supports esomeprazole as an effective treatment for maintenance of remission and prevention of treatment failure in gastroesophageal reflux disease patients with EE. 
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